SEC Form 4 · accession 0001144204-18-031178

PHIBRO ANIMAL HEALTH CORP · PAHC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director · 10% Owner

Period of report

Mar 23, 2018

Accepted (ET)

May 25, 2018 · 8:13 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001069899

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Class A Common Stock^F1,F2,F3	Mar 23, 2018	C	58,000	$0.00	A	60,070	I	See
Class A Common Stock^F2,F4,F3	Mar 23, 2018	S	1,900	$45.12	D	58,170	I	See
Class A Common Stock^F2,F5,F3	Mar 24, 2018	S	600	$45.01	D	57,570	I	See
Class A Common Stock^F2,F3	Mar 25, 2018	S	100	$45.05	D	57,470	I	See

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Class B Common Stock^F1,F2,F3	$0.00	Mar 23, 2018	C	58,000	D	—	—	Class A Common Stock	58,000	20,458,034	I

F1Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, and has no expiration date.
F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017.
F3The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.38, inclusive.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.05, inclusive.